ArticleJournal of cancer research and clinical oncology2022

Does first-line immunotherapy impact the efficacy of later treatments: a discussion on the use of second progression-free survival as a research endpoint.

Zhening Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.